Lung cancer is the leading cause of cancer mortality. In some countries, incidence rates are dropping but survival rates for those with the disease remain low. By Eric Bender.
Marks of a killer: Lung physiology
Lung cancer is categorized by cell type into non-small-cell lung cancer — of which the three main subtypes are adenocarcinoma, squamous cell carcinoma and large cell carcinoma — and small-cell lung cancer. Treatment and prognosis differ depending on the type of lung cancer1.
Marks of a killer: The main types of lung cancer
A world of risk
Annual incidence risks of lung cancer per 100,000 people in 2012. Tobacco is the main cause of the disease, but about one-tenth of lung-cancer patients have never smoked5.
A world of risk: Estimated worldwide cancer mortality, 2012
Public-health case study: United Kingdom — lung cancer risk factors
Estimated causes of lung cancer in Britain, 20142. Most cases of lung cancer are attributable to smoking, and so could be prevented.
Public-health case study: Worldwide — lost years
The impact of the disease is climbing quickly in China, as a result of the rapidly increasing number of smokers (see 'Public-health case study: China — Smoke rises', below')3.
Public-health case study: China — smoke rises
The population of smokers, dominated by men, continues to rise in China, where tobacco kills an estimated 3,000 people a day3,4.
Public-health case study: South Africa — cigarette consumption and cost
Around the world, higher taxes on tobacco lower smoking rates. In South Africa6,7, overall retail prices have risen substantially since 1991 and cigarette sales have plummeted.
Public-health case study: United States — annual price of lung cancer
Change history
12 September 2014
References
US National Cancer Institute, Surveillance, Epidemiology, and End Results Program Cancer Statistics Review 1975–2011
Cancer Research UK
Institute for Health Metrics and Evaluation, University of Washington
International Agency for Research on Cancer, World Cancer Report (2014)
International Agency for Research on Cancer
Belcher, E. Tob. Control 19, 325–330 (2010)
Institute for Health Metrics and Evaluation, University of Washington
US National Cancer Institute Cancer Trends Progress Report 2011/2012
US Centers for Disease Control and Prevention
Roth, J. A . et al. J. Clin. Oncol. 32 (Suppl.), 6501 (2014)
United States Centers for Disease Control and Prevention
US National Cancer Institute Cancer Trends Progress Report 2011/2012
Rights and permissions
About this article
Cite this article
Bender, E. Epidemiology: The dominant malignancy. Nature 513, S2–S3 (2014). https://doi.org/10.1038/513S2a
Published:
Issue Date:
DOI: https://doi.org/10.1038/513S2a
This article is cited by
-
Integration of single sample and population analysis for understanding immune evasion mechanisms of lung cancer
npj Systems Biology and Applications (2023)
-
LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer
Cell Death & Disease (2023)
-
Eupafolin regulates non-small-cell lung cancer cell proliferation, migration, and invasion by suppressing MMP9 and RhoA via FAK/PI3K/AKT signaling pathway
Journal of Biosciences (2023)
-
Genetic profiling of primary and secondary tumors from patients with lung adenocarcinoma and bone metastases reveals targeted therapy options
Molecular Medicine (2020)
-
Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer
Oncogene (2020)